Brief Report: Role of Sociobehavioral Factors in Subprotective TFV-DP Levels Among YMSM Enrolled in 2 PrEP Trials : JAIDS Journal of Acquired Immune Deficiency Syndromes

Secondary Logo

Journal Logo

Prevention Research

Brief Report: Role of Sociobehavioral Factors in Subprotective TFV-DP Levels Among YMSM Enrolled in 2 PrEP Trials

Arrington-Sanders, Renata MD, MPH, ScM*; Wilson, Craig M. MD; Perumean-Chaney, Suzanne E. PhD; Patki, Amit MSc§; Hosek, Sybil PhD

Author Information
JAIDS Journal of Acquired Immune Deficiency Syndromes: February 1, 2019 - Volume 80 - Issue 2 - p 160-165
doi: 10.1097/QAI.0000000000001901
  • Free



Young men who have sex with men (YMSM) disproportionately are impacted by HIV, with young Black men experiencing the greatest burden of HIV disparities.1,2 Daily oral pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine has been shown to effectively prevent HIV transmission in YMSM3,4; however, recent studies suggest that young Black men who have sex with men (YBMSM) experience subprotective levels of tenofovir diphosphate (TFV-DP) more frequently than other groups, potentially predisposing them to HIV acquisition despite use.5,6

TFV-DP levels greater than 4 pills per week (≥700 fmol/punch) have been associated with high levels of protection against rectal HIV exposure.7 Data from the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 110/113 studies demonstrated a decline in adherence over the course of the 48-week follow-up in all participants, with subprotective levels beginning to occur around 12 weeks. YBMSM, however, had subprotective levels at all time points, with median levels below the protective threshold of 4 pills per week (<700 fmol/punch).5 There is a lack of clarity as to why YBMSM have subprotective TFV-DP levels compared with other groups; however, previous work suggests that the lower levels are not attributed to biological differences.8

Sociobehavioral factors that predispose all YMSM to HIV risk, such as low perceived HIV risk and stigma, may be further compounded by unstable housing and poor family support, further contributing to medication nonadherence and lower protective TFV-DP levels in YBMSM.9 The objectives of this study were to examine sociodemographic and behavioral factors associated with protective TFV-DP levels (defined as >700 fmol/punch).


Combined data from ATN 110/113, 2 open-label PrEP studies that provided PrEP and evidence-based behavioral interventions to YMSM aged 15–22 years, were analyzed to examine the objective of this study. In these studies, participants were followed through study visits at baseline and monthly for 3 months, and then quarterly through week 48. At each visit, participants completed behavioral assessments that included reasons for and frequency of missing PrEP through an audio computer-assisted self-interview, received condoms, and were provided study drug.10 Participants were provided compensation for each study visit as determined by the Institutional Review Board at each site (range $50–75). A full description of the studies is published elsewhere.5,6

Dried blood spots collected at each visit were used to quantify intracellular TFV-DP concentrations in red blood cells.11 For the purpose of this analysis, primary outcome was defined as protective (≥700 or more fmol per punch) and subprotective levels defined as a TFV-DP level <700 fmol/punch.

The main predictor examined of protective level was Black/African American versus non-Black race. We additionally examined potential factors associated with optimal TFV-DP levels including age (younger: 15–18 years vs. older: 19–22 years), Hispanic ethnicity, housing status (living in or outside the presence of parents/guardian and history of being kicked out of the home due to sexual orientation), condom nonuse, substance use, perceived risk of acquiring HIV, and self-reported reasons for discontinued use. Age group categories were based on sample size, so that each group would have approximately the same number of participants. Self-reported reasons for discontinued use were dichotomized (no/yes) from a four-point scale (1 = Never, 2 = Rarely, 3 = Sometimes, and 4 = Often) as the majority of the subjects indicated never discontinuing use (83.1%–97.0%).

Bivariate analyses were used to explore associations between the main predictor variable and potential variables that might impact adherence at 4, 8, 12, and 24-week follow-up time points in separate models. Variables significant (P < 0.10) in the bivariate analyses for each time point were included in logistic regression models. Interaction terms were explored between age and race. The 4 forward stepwise regression models (weeks 4, 8, 12, and 24) included race, age, and the specific significant bivariate covariates for that specific time point. We compared full model analyses with forward stepwise regression models. We chose the more parsimonious stepwise models. Backward stepwise regression models verified the selected models. We further explored factors associated with optimal adherence at each time point in YBMSM only and by age to examine specific factors that might impact adherence in YBMSM and whether factors significant at each time point mediated the relationship between race and blood levels.

To adjust for multiple comparisons across time, we used the Bonferroni correction for the logistic regression models to determine significant predictors [P-value <0.0125 (α = 0.05/4 time points)].


Participant characteristics are presented in Table 1. At baseline, the mean age of the sample was 19.12 ± 2.01 years. Most participants self-identified as African American/Black (55%), were living with parents/guardians (47%), and described prior alcohol (82%) or marijuana use (55%). One-fifth (19.2%) of participants described sexually transmitted infection in the past year, being displaced due to sexual orientation (18%), and over one-third described condom nonuse during receptive (38.9%) or insertive (38.1%) sex. Overall, subprotective TFV-DP levels (51.1%) were common, with Black participants having TFV-DP levels at all time points that were subprotective (range 495.90–649.70).

Overall Variables by TFV-DP Levels

In bivariate analysis (Table 1), self-identified Black participants were less likely to have protective TFV-DP levels at all time points. At 4 weeks, persons who self-reported not taking medications because of feeling depressed/overwhelmed, not engaging in risky sex, and belief that medications were toxic/harmful were less likely to have protective TFV-DP levels than participants who did not report these reasons. At 8 weeks, persons who had history of being kicked out of their home, not taking medications because of feeling depressed/overwhelmed, not engaging in risky sex, belief that medications were toxic, and desire for others not to see medications were less likely to have protective TFV-DP levels than participants who had not been kicked out or did not report these reasons. Hispanic participants were more likely to have protective levels at 12 weeks than non-Hispanic participants. At 12 and 24 weeks, persons who had history of being kicked out of their home, not engaging in risky sex, and desire for others not to see medications were less likely to have protective TFV-DP levels than participants who had not been kicked out or did not report these reasons. Age was significant at 24 weeks, with older participants more likely to have protective levels than younger participants. An interaction between age and race was seen at 8 weeks with older (19–22 years) non-Black participants more likely to have protective blood levels than younger Black participants, and older (age 19–22) Hispanic participants at 4 and 8 weeks more likely to have protective levels than non-Hispanic participants of the same age. However, no difference was noted in level of protection for Hispanic Black participants.

Using logistic regression modeling, at 4 and 8 weeks, Black participants were less likely to have optimal protective levels than non-Black participants (68% and 55%, respectively, Table 2). At week 12, Black participants were 59% less likely than non-Black participants to have protective levels. Participants who reported being kicked out of the house were 81% less likely than participants who were not kicked out of the house to have protective levels. Older participants were 1.97 times more likely to have protective levels than younger participants. At week 24, older participants (ages 19–22) were 2.4 times more likely than younger participants (ages 15–18) to have protective levels. Perception of risk also approached significance at 12 and 24 weeks with participants who reported missing their medication because they were not having risky sex being 91.6% and 92% (odds ratio, 95% confidence interval: P-value 0.022; odds ratio, 95% confidence interval: P-value 0.016, respectively) less likely than participants who did not report this reason to have protective TFV-DP levels, respectively.

Variables Associated With ≥700 TFV-DP Levels

In the logistic regression models examining factors associated with protective levels in Black participants only (Table 2), at 12 weeks, Blacks who described having been kicked out were 86.6% less likely to have optimal TFV-DP adherence compared to those who reported not being kicked out. No variables were significant at any of the time points in the logistic regression models of younger (ages 15–18) Black participants. In older (ages 19–22) Black participants, having been kicked out of one's home was significant at 12 weeks, indicating that those who were kicked out were 95.2% less likely to have protective levels than those who reported they were not kicked out (P = 0.005). At 24 weeks, self-reported displacement nears significance in the same direction with a P-value of 0.027. No factors significant at each time point mediated the relationship between race and blood levels.


In this evaluation of ATN 110 and 113 data, we found that self-identified YBMSM were less likely to have therapeutic levels of TFV-DP across all data points. Potential vulnerabilities, including displacement due to sexual orientation, low perceived risk, and stigma associated with medications, impacted optimal adherence and need to be critically addressed to implement PrEP in adolescents.

Nearly 20% of youth reported having been displaced due to sexual orientation. Residential instability has been associated with HIV risk–related behaviors including higher number of sexual partners and history of sexually transmitted infections.12 Other studies have described an association between residential displacement and vulnerability, particularly among young men of color, whereas family connectedness and support have been protective.13–15 Displacement may be even more critical for YBMSM who may be already experiencing isolation, marginalization, and homophobia within Black communities and across other sexual and gender minority communities.16 One approach is to develop interventions specifically for parents and families of young gay, lesbian, bisexual, or questioning youth to ameliorate the conflict that can arise as an adolescent begins to explore their same-sex sexual attractions.12 This work also calls for policy measures that expand housing for young men who may experience residential displacement and instability as a result of their sexual orientation due to the high risk of HIV acquisition during displacement.

Older participants were 2 times more likely to have therapeutic levels than younger participants. This finding suggests that younger adolescents have some specific developmental and cognitive needs that are required to successfully navigate PrEP use. Some have suggested that younger adolescents will require not only additional visits than what is currently recommended by national guidelines, but also team members who can address these needs and help youth incorporate PrEP into their daily lives.17 The ability to develop abstract thinking, plan for one's future, and integrate a positive adult identity, while simultaneously managing potential disapproval of same-sex behavior and daily medications for HIV prevention, is likely to require an interdisciplinary developmentally centered approach needed to support optimal adherence.

In the United States, rates of HIV acquisition in adolescents are highest in YMSM.18,19 YBMSM experience some of the greatest health disparities, with studies suggesting that 40% of YBMSM will acquire HIV by 40 years unless prevention efforts improve.20 The health disparities inherent in the U.S. epidemic are heightened in the what we know about tenofovir/emtricitabine uptake in Black men who have sex with men.21 In 2012–2015, only 11.5% of the prescriptions filled by youth younger than 25 years were prescribed to non-Hispanic Black users.22 Self-reported use in YBMSM samples has been estimated at closer to 8% in YBMSM,23 and recent work suggests that YBMSM experience the lowest rates of uptake,24 despite having greatest indications for PrEP.21

Stigma associated with the medication and low risk perception have been identified as key barriers to PrEP use.5,6,25 We found that adherence was associated with not engaging in “risky sex” and fear others would see the medications. Confidentiality concerns about PrEP, including disclosure of one's sexual behavior and sexual orientation to parents/guardians, has been described as a barrier to YMSM26 and may further prevent access to PrEP for youth who are most vulnerable.

In order for biomedical interventions to be effective, researchers, health care providers, and policy makers will need to better understand and address how PrEP is received in at-risk YMSM, as well as develop approaches that address such barriers. Previous work suggests that PrEP is perceived as promoting “risky sexual practices” or only for individuals engaging in sex with multiple partners.25 This assumption excludes persons in serodiscordant relationships and focuses on individual risk behavior, leaving out partners who may be located in networks of high HIV prevalence.27 The findings of this study calls for work that explores ways in which YMSM process sexual risk and develops interventions that promote uptake of PrEP, addresses the stigma of taking a medication for HIV, and provide needed protections (eg, access to needed housing) during disclosure of sexual orientation.

There are some limitations of these data that should be noted. Both ATN 110/113 data sets were small open-label studies and may not reflect how YMSM apply and use PrEP in their daily lives. The size of the data sets may have limited our ability to identify associations. Despite these limitations, the findings of this work suggest key areas of intervention for PrEP in YMSM.


These findings have important implications with respect to both future behavioral research and biomedical prevention efforts. Research is needed to better understand why suboptimal adherence may be a relatively common occurrence among YMSM who are attempting to adhere to daily PrEP use, and why some populations, particularly Black and younger MSM, may be especially vulnerable to subprotective levels. Effective PrEP interventions will need to address not only the developmental, cognitive, and risk perception of the individual, but also incorporate the family support and community contexts that may further promote risk for YMSM. Particularly, the lack of key supportive housing during this period may be one critical factor that will need to be addressed in future PrEP interventions.


The investigators are grateful to the members of the local Youth Community Advisory Boards for their insight and counsel and are particularly indebted to the young men who participated in this study and their willingness to share their lives and time with us.


1. Balaji AB, An Q, Smith JC, et al. High human immunodeficiency virus incidence and prevalence and associated factors among adolescent sexual minority males-3 cities, 2015. Clin Infect Dis. 2018;66:936–944.
2. Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States, 2010–2015. HIV Surveillance Supplemental Report. Vol 23, ch 1; 2018. Available at: Accessed August 1, 2018.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–2599.
4. Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176:75–84.
5. Hosek SG, Rudy B, Landovitz R, et al. An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr. 2017;74:21–29.
6. Hosek SG, Landovitz RJ, Kapogiannis B, et al. Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 Years in the United States. JAMA Pediatr. 2017;171:1063–1071.
7. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820–829.
8. Liu A, Glidden DV, Anderson PL, et al. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr. 2014;67:528–537.
9. Arnold T, Brinkley-Rubinstein L, Chan PA, et al. Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. PLoS One. 2017;12:e0172354.
10. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med. 2000;50:1599–1605.
11. Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29:384–390.
12. Kipke MD, Weiss G, Wong CF. Residential status as a risk factor for drug use and HIV risk among young men who have sex with men. AIDS Behav. 2007;11(suppl 6):56–69.
13. D'Augelli A, Hershberger SL. Lesbian, gay, and bisexual youth in community settings: personal challenges and mental health problems. Am J Community Psychol. 1993;21:421–448.
14. Sneed C, Morisky D, Rotheram-Borus MJ, et al. Patterns of adolescent alcohol, cigarette, and marijuana use over a six-month period. Addict Behav. 2001;26:415–423.
15. Tucker JS, Hu J, Golinelli D, et al. Social network and individual correlates of sexual risk behavior among homeless young men who have sex with men. J Adolesc Health. 2012;51:386–392.
16. Fields E, Morgan A, Arrington Sanders R. The intersection of sociocultural factors and health-related behavior in lesbian, gay, bisexual, and transgender youth: experiences among young Black gay males as an example. Pediatr Clin North Am. 2016;63:1091–1106.
17. Arrington-Sanders R. Human immunodeficiency virus preexposure prophylaxis for adolescent men: how do we ensure health equity for at-risk young men? JAMA Pediatr. 2017;171:1041–1042.
18. World Health Organization. Policy Brief: Pre-exposure Prophylaxis (PrEP): WHO Expands Recommendation on Oral Pre-exposure Prophylaxis of HIV Infection (PrEP). World Health Organization; 2015. Available at: Accessed June 3, 2018.
19. UNAIDS. How AIDS Changed Everything. Millennium Development Goals, 2015. Available at: Accessed June 3, 2018.
20. Koblin BA, Mayer KH, Eshleman SH, et al. Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061. PLoS One. 2013;8:e70413.
21. Smith DK, Van Handel M, Grey JA. By Race/Ethnicity, Blacks Have Highest Number Needing PrEP in the United States. Boston, MA: CROI; 2018.
22. Bush SMD, Rawlings MK, Hawkins T, et al. Racial Characteristics of FTC/TDF for Pre-exposure Prophylaxis Users in the US. Boston, MA: ASM Microbe; 2016.
23. Arrington-Sanders R, Morgan A, Oidtman J, et al. A medical care missed opportunity: preexposure prophylaxis and young Black men who have sex with men. J Adolesc Health. 2016;59:725–728.
24. Kuhns LM, Hotton AL, Schneider J, et al. Use of pre-exposure prophylaxis (PrEP) in young men who have sex with men is associated with race, sexual risk behavior and peer network size. AIDS Behav. 2017;21:1376–1382.
25. Eaton LA, Kalichman SC, Price D, et al. Stigma and conspiracy beliefs related to pre-exposure prophylaxis (PrEP) and interest in using PrEP among Black and white men and transgender women who have sex with men. AIDS Behav. 2017;21:1236–1246.
26. Fisher CB, Fried A, Ibrahim Puri L, et al. “Free testing and PrEP without outing myself to parents:” Motivation to participate in oral and injectable PrEP clinical trials among adolescent men who have sex with men. PLoS One. 2018;13:e0200560.
27. Arrington-Sanders R, Fields E, Greenberg L, et al. Does venue type matter for HIV-related risk behavior in urban adolescent and young adult men who have sex with men? Youth Soc. 2017. doi: 10.1177/0044118X17723655.

young men who have sex with men; pre-exposure prophylaxis; HIV prevention

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.